Recurrent hypoglycemia triggered by sorafenib therapy in a patient with hemangiopericytoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Si Won | - |
dc.contributor.author | Lee, Eun Kyung | - |
dc.contributor.author | Yun, Tak | - |
dc.contributor.author | Won, Young-Woong | - |
dc.contributor.author | Ko, Eun Jeong | - |
dc.contributor.author | Choi, Mihong | - |
dc.contributor.author | Choi, Sang Il | - |
dc.contributor.author | Park, Sun Seob | - |
dc.contributor.author | Hong, Eun Kyung | - |
dc.date.accessioned | 2022-07-16T04:28:41Z | - |
dc.date.available | 2022-07-16T04:28:41Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159811 | - |
dc.description.abstract | Targeted therapy has been proven to be one of the most effective cancer treatments. However, some endocrine disorders can occur during treatment with targeted agents. We report the case of a patient who exhibited a wax and wane pattern of hypoglycemia that was attributed to sorafenib therapy. A 32-year-old woman with metastatic hemangiopericytoma visited the emergency department in a stuporous state. Nonhyperinsulinemic hypoglycemia was diagnosed, was exacerbated shortly after sorafenib therapy, and was improved by the cessation of sorafenib with additional glucocorticoid therapy. Patients with metastatic hemangiopericytoma should be carefully monitored with particular attention to hypoglycemia when sorafenib therapy is initiated. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Endocrine Society | - |
dc.title | Recurrent hypoglycemia triggered by sorafenib therapy in a patient with hemangiopericytoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Won, Young-Woong | - |
dc.identifier.doi | 10.3803/EnM.2014.29.2.202 | - |
dc.identifier.scopusid | 2-s2.0-84975760116 | - |
dc.identifier.bibliographicCitation | Endocrinology and Metabolism, v.29, no.2, pp.202 - 205 | - |
dc.relation.isPartOf | Endocrinology and Metabolism | - |
dc.citation.title | Endocrinology and Metabolism | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 202 | - |
dc.citation.endPage | 205 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001882567 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Hemangiopericytoma | - |
dc.subject.keywordAuthor | Hypoglycemia | - |
dc.subject.keywordAuthor | Sorafenib | - |
dc.identifier.url | https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2014.29.2.202 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.